Not long after politicalcandidates pointed to astronomical drug prices on the debate stage,new analysis showed that the average price of new brand-name drugsskyrocketed in the last decade. Current and future politicianslinger in a limbo of promises that can't be immediately acted on.To date, most governmental drug pricing proposals have been delayedor rescinded by the Trump administration. And pharmaceuticalindustry regulators, too, have been slow to make much progress ondrug prices within a Byzantine mire of authorities.
Meanwhile, pharmacy giants are in a feeding frenzy, withtransactions like Amgen's purchase of Celgene's psoriasis drugclearing a roadblock for Bristol-Myers Squibb's acquisition ofCelgene.
Drug companies are getting bigger and health care costs keepgoing up. What can employers do now to fight back in this Davidversus Goliath setup, as the sides become increasingly uneven?
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
